Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward.

The efficacy of medicines, medical devices, and other health technologies should be proved in trials that assess final patient-relevant outcomes such as survival or morbidity. Market access and coverage decisions are, however, often based on surrogate end points, biomarkers, or intermediate end points, which aim to substitute and predict patient-relevant… CONTINUE READING